TAKE Limited Q1 FY27: Net Profit Rs 1.06 Cr on Revenue Rs 30.37 Cr

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

TAKE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹23.25

prior close

₹23.94

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+1.1% vs market

Healthcare Research Analytics & Technology peers, median of 5sector-0.8%+2.2% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 2.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.2

15m

-1.0

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.4+1.1-0.8+2.2

Next day

+2.1+0.5+1.6-1.7+3.8

+3.1+0.6+2.5-1.5+4.6

-0.4+0.7-1.2-1.4+1.0

+0.8+1.1-0.3+0.1+0.7

-1.5+0.5-2.0-2.6+1.1

-10.8+1.3-12.0-0.0-10.7

15d

-40.4+0.5-40.9+5.3-45.7

-20.5-0.8-19.6-2.0-18.5

-45.4-0.9-44.5-8.3-37.1

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 unaudited results. Consolidated revenue at Rs 30.37 cr versus nil YoY. Net profit Rs 1.06 cr versus loss of Rs 91 lakh YoY. Finance costs down 99.6 percent to near zero. EPS positive at Rs 0.07. Standalone revenue Rs 11.97 cr, net profit Rs 96.83 lakh. Auditor gave clean limited review. Company announced entry into biohacking and longevity segment.

Likely market impact

Sharp revenue growth and return to profitability signal positive momentum; near-zero debt burden improves capital structure for shareholders.